Investorideas.com Newswire

Investorideas.com Newswire
Be one of the most talked about companies (stocks) on social media

Saturday, February 26, 2011

Investorideas.com list of biotech stocks updated for March 2011

Biotech Stocks Directory for  March 2011

Full directory - http://www.investorideas.com/membership/



3SBio Inc. (NasdaqGS:SSRX) is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. With headquarters and GMP certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 500 people.

A5 Laboratories Inc. (OTCBB:AFLB) is a contract research based organization servicing the pharmaceutical and biotechnology companies in North America. The company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercialization.

Aastrom Biosciences, Inc. (NasdaqCM: ASTM) is developing expanded autologous cellular therapies for the treatment of severe cardiovascular diseases. The company's proprietary cell manufacturing technology enables the production of cellular therapies expanded from a patient's own bone marrow and delivered directly to damaged tissues. Aastrom has advanced its cell therapies into late-stage clinical development, including a planned Phase 3 clinical program for the treatment of patients with critical limb ischemia and two ongoing Phase 2 clinical trials in patients with dilated cardiomyopathy.

ABBOTT LABORATORIES (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs nearly 90,000 people and markets its products in more than 130 countries.

Abviva, Inc (OTCPK:ABVV) was established to develop and commercialize diagnostic and therapeutic products from a novel breast cancer growth inhibitory protein. Research scientists at the prestigious University of Michigan Cancer Center discovered a secreted protein produced in normal breast epithelial cells that inhibits the growth of breast cancer. This discovery was developed into a diagnostic blood test for breast cancer, Mammastatin Serum Assay (MSA). The MSA will be used to screen women for early detection of breast cancer. In clinical studies Mammastatin was found to be normally present in blood serum of healthy women and absent in women with breast cancer. Abviva intends to offer the MSA to women and their doctors through its wholly owned clinical reference laboratory, Biomedical Diagnostics, LLC.

Acadia Pharmaceuticals Inc. (NasdaqGM: ACAD) is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA has a portfolio of four product candidates including pimavanserin, which is in Phase III clinical development as a treatment for Parkinson’s disease psychosis. ACADIA also has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, as well as a product candidate in IND-track development for schizophrenia in collaboration with Meiji Seika Kaisha. All of the product candidates in ACADIA’s pipeline emanate from discoveries made using its proprietary drug discovery platform.

Accentia Biopharmaceuticals, Inc. (OTCPK:ABPI) is committed to building significant value for its stockholders through the commercialization of patent-protected disruptive healthcare technologies designed to be positioned as leading products for the treatment of a broad range of chronic, debilitating and life-threatening diseases including respiratory, autoimmune and cancer indications. Accentia is advancing a portfolio of potential blockbuster drug candidates which target multi-billion dollar market opportunities. These late-stage products include: BiovaxID®, a novel anti-idiotype cancer vaccine for the treatment of B-cell malignancies including indolent follicular non-Hodgkin's lymphoma; Revimmune™, a novel ultra-high-dose formulation of a previously approved chemotherapeutic agent expected to show utility in the treatment of up to 80 autoimmune diseases, with an initial focus on multiple sclerosis; and SinuNase™, a novel formulation of a previously approved anti-fungal for the topical, intranasal treatment of chronic sinusitis. Accentia's interest in BiovaxID is based on its majority ownership stake in Biovest International, Inc., and Accentia also maintains a royalty interest in Biovest's biologic products.

Access Pharmaceuticals, Inc. (OTCBB:ACCP) is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include ProLindac™, currently in Phase II clinical testing of patients with ovarian cancer, and MuGard™ for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin™-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers.



Full directory - http://www.investorideas.com/membership/



More Investorideas Biotech Stocks info wwww.BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks, Biotech, Pharma and Industry News and Biotech Investor Research Tools including a Biotech Stocks Directory Biotech Companies - become a biotech showcase stock on www.investorideas.com and www.biotechindustrystocks.com for as little as $1000 month !

Thursday, February 24, 2011

Biotech/Pharma Stock News; BioSante Pharmaceuticals (NASDAQ: BPAX) Completes Enrollment in LibiGel® Phase III Efficacy Trial

LINCOLNSHIRE, Ill. - February 24, 2011 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), today announced that enrollment of subjects in the first of two pivotal Phase III LibiGel (testosterone gel) safety and efficacy trials has been completed. The efficacy trials are being conducted under an FDA-approved special protocol assessment (SPA) agreement. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product.
"This is an important milestone for BioSante. This achievement represents a key positive step toward completing the LibiGel Phase III clinical development program. To date, we have a combined enrollment in our three LibiGel Phase III clinical studies of approximately 4,000 women and we anticipate announcing completion of enrollment in the second efficacy trial very soon," said Joanne Zborowski, BioSante's vice president of clinical development.
About LibiGel®
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD). The on-going Phase III efficacy trials are double-blind, placebo-controlled trials that will enroll approximately 500 surgically menopausal women each. The efficacy trials are being conducted under an FDA-approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time.
In a Phase II trial, LibiGel significantly increased the number of satisfying sexual events in surgically menopausal women suffering from FSD by 238 percent versus baseline (p &tl; 0.0001); this increase also was significant versus placebo (p &tl; 0.05). In this study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. In addition, no serious adverse events and no discontinuations due to adverse events occurred in any subject receiving LibiGel. The Phase II clinical trial was a double-blind, placebo-controlled trial, conducted in the United States, in surgically menopausal women distressed by their low sexual desire and activity.
BioSante also is conducting a Phase III LibiGel safety study, a randomized, double-blind, placebo-controlled, multi-center, cardiovascular (CV) events and breast cancer study that has enrolled 2,869 women. The study will continue for a total of five years, however, BioSante can use the safety study data as part of an NDA submission after an average of 12 months of exposure to LibiGel or placebo.
The LibiGel safety study is tracking a predefined list of CV events, in agreement with the FDA, including CV death, myocardial infarction and stroke in women 50 years of age or older and suffering from at least two CV risk factors including hypertension and diabetes. The objective of the safety study is to show the relative safety of testosterone compared to placebo in the number of CV events. The incidence of breast cancer also is being tracked over the course of the study. To date, there have been 17 adjudicated cardiovascular (CV) events, a lower than anticipated rate of approximately 0.57 percent. There have been eight breast cancers reported, a rate of approximately 0.27 percent.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as �will,� �potential,� �could,� �can,� �believe,� �intends,� �continue,� �plans,� �expects,� �anticipates,� �estimates,� �may,� other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com

Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com (1000 per month).

Wednesday, February 23, 2011

Q&A Interview with BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX); Update on LibiGel Phase III Clinical Development Program

February 23, 2011 - (Investorideas.com newswire.com) Investorideas.com, an investor research portal covering leading sectors including biotech stocks and pharma stocks, presents the fourth in a series of Q&A interviews with Stephen M. Simes, President and CEO of BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX). Mr. Simes updates the investment community on recent milestones for its leading product in development, LibiGel (testosterone gel).
The first introductory Q&A can be found here:
http://www.investorideas.com/CO/BPAX/news/9211.asp
In this follow up, Stephen M. Simes, president and chief executive officer of BioSante Pharmaceuticals discusses recent developments with LibiGel (testosterone gel).
Interview
Q: Investorideas.com
Stephen, can you give us a quick summary of some of the company's recent milestones?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
The most recent milestone regarding LibiGel is a very positive LibiGel safety data update. We reported that the safety study's independent Data Monitoring Committee (DMC) took its fifth unblinded look at adverse events reported in the LibiGel safety study. For the fifth time, the DMC recommended continuing the LibiGel safety study as per FDA-agreed protocol without modification. This is a positive outcome since the DMC did not express to us any concern to date about the safety of LibiGel.
Q: Investorideas.com
Your company just recently announced t hat there has been positive safety data in your ongoing LibiGel Phase III clinical trials. Your news release states "with 2,869 women enrolled and over 3,000 women-years of exposure in its LibiGel Phase III cardiovascular and breast cancer safety study, there have been 17 adjudicated cardiovascular (CV) events, with a lower than anticipated event rate of approximately 0.57 percent. There have been eight breast cancers reported, a rate of approximately 0.27 percent." With those positive safety results how much closer to FDA approval does that make LibiGel?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
We are making excellent progress toward FDA approval in that our three LibiGel Phase III clinical studies are proceeding as per our plan. Our hope is to submit a new drug application (NDA) to the FDA for a LibiGel approval and launch in 2012. This is on the near-term horizon for us.
Q: Investorideas.com
Your company recently presented data at an International conference showing Female Sexual Dysfunction is a significant unmet medical need. Can you give us a summary of some the physician stats to back that up?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
To start, it is important to point out that there is no FDA-approved pharmaceutical product for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD). Well over 80 percent of surveyed physicians told us that there is a need or a great need for an FDA-approved product for the treatment of female sexual dysfunction, a full 13 years after Viagra was approved for men. In fact, over 90 percent of surveyed physicians report that they currently prescribe products off-label (that is, products not FDA-approved) for the treatment of FSD. Interestingly the average gynecologist hears 37 non-solicited complaints about FSD per month. The unmet medical need is dramatic.
Q: Investorideas.com
You recently stated. "LibiGel remains the only product in the world in Phase III clinical development for the treatment of HSDD". Can you comment in more detail on the significance of that?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
As I mentioned, there is no FDA-approved pharmaceutical product for the treatment of HSDD. LibiGel is the only product in the world in Phase III clinical development for this indication. Therefore, we expect to be the first product to be FDA approved for HSDD!
Q: Investorideas.com
As the biotech sector is heating up again for investors, your company has received substantial media attention recently, in particular following your company reporting positive safety data from your late-stage study. The company plans to submit an application for LibiGel's approval to the Food and Drug Administration in 2012 - so what key developments are in the pipeline for investors and media to watch for from now to then?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
In the very near-term, we hope to announce completion of enrollment in our LibiGel efficacy trials. In addition, we will continue to report on data from our LibiGel safety study, even though we remain blinded to which therapy, LibiGel or placebo, the women in the study are taking. LibiGel is the main driver of value for BioSante in 2011, however, we also expect to update the public about our other products in development including Bio-T-Gel, our male testosterone gel, already licensed to TEVA, as well as our cancer vaccines in development.
About LibiGel®
LibiGel® is a gel formulation of testosterone in development that is quickly absorbed through the skin after a once-daily application of a pea-sized dose of gel on the upper arm, delivering testosterone to the bloodstream evenly over time and in a non-invasive and painless manner. Though generally characterized as a male hormone, testosterone also is present in women and its deficiency has been found to decrease libido or sex drive. In addition, studies have shown that testosterone therapy can increase bone density, raise energy levels and improve mood, in addition to boosting sexual desire and activity.
Currently, BioSante is conducting three Phase III clinical studies to demonstrate the safety and efficacy of LibiGel to increase sexual desire and satisfying sexual events and to decrease distress associated with the decreased desire. Two Phase III safety and efficacy trials that are underway are randomized, doubleblind, placebo-controlled trials which will enroll approximately 500 surgically menopausal women each for six-months of treatment. BioSante is conducting these trials under an FDA agreed special protocol assessment (SPA). In addition, BioSante has another SPA agreement with the FDA related to treatment of naturally menopausal women. The SPA process and agreement confirms the FDA's position that FSD and HSDD are true conditions that women experience, with measurable endpoints, that can be evaluated and which deserve therapeutic options. It also affirms that the FDA agrees that the LibiGel Phase III safety and efficacy clinical trial design, clinical endpoints, sample size, planned conduct and statistical analyses are acceptable to support regulatory approval. Further, it provides assurance that these agreed measures will serve as the basis for regulatory review and the decision by the FDA to approve an NDA for LibiGel.
About BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX)
BioSante (NASDAQ: BPAX) is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Visit the company profile on Investorideas.com: http://www.investorideas.com/CO/BPAX/
Or the company website www.biosantepharma.com to learn more about BioSante.
Request News & Updates from BioSante (NASDAQ: BPAX) on the Investorideas.com sign up page: http://www.investorideas.com/Resources/Newsletter.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing covering over thirty industry sectors and global markets including China, India, the Middle East and Australia. Our leading biotech portal within our content umbrella, www.BiotechIndustryStocks.com, covers the biotech/pharma sector for independent investors with company profiles, news and stock directories.
Disclaimer: The following BioSante Pharmaceuticals, Inc company profile is a paid for submission (one thousand per month) Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions, company profile submissions and online advertising. http://www.investorideas.com/About/Disclaimer.asp
Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
For info about BioSante Pharmaceuticals, Inc
Contact:
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953; tswanson@troutgroup.com
For Additional Information about Investorideas.com:
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com

Tuesday, February 22, 2011

Biotech/Pharma Stock News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) to Present at Citi Global Health Care Conference

LINCOLNSHIRE, Ill. - February 22, 2011 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will be presenting at the 2011 Citi Global Health Care Conference. The conference will take place March 1-3, 2011 at the Hilton Hotel in New York City, New York.
Stephen M. Simes, BioSante�s president & CEO, will speak Tuesday, March 1, 2011 at 2:30 pm EST. He will provide an overview of the company, as well as an update on the LibiGel® (testosterone gel) Phase III clinical development program. A live audio webcast of Mr. Simes� remarks may be accessed at: http://www.veracast.com/webcasts/citigroup/healthcare2011/88112623.cfm. A webcast replay will be available one hour after conclusion of the presentation and will expire June 1, 2011.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com

Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com (1000 per month).

Friday, February 18, 2011

Biotech/Pharma Stock News; Regulatory Process Is an Ongoing Challenge for Xoma & BioSante (NASDAQ: BPAX)

NEW YORK, NY - February 18, 2011 (Investorideas.com newswire) There is plenty of optimism surrounding the Biotech industry as firmer pricing and new products have improved sales and earnings trends. Meanwhile, more speculative biotech firms such as XOMA and BioSante continue to garner significant attention with potential blockbuster drugs working their way through the regulatory process.The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides research reports on XOMA, Ltd. (NASDAQ:XOMA) and BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX). Access to the full company reports can be found at: www.bedfordreport.com/2011-02-XOMA www.bedfordreport.com/2011-02-BPAX
A recent study released by BIO and BioMedTracker claims that the success rate in bringing new medicines to market in the past six years is only about half of what it had been previously. The study claims, however that biotech drugs are twice as likely to gain approval than more traditional chemical drugs.
The study found that drugs moving from early stage Phase I clinical trials to FDA approval is roughly ten percent, down from around 20 percent in reports involving earlier years.The report adds that approval applications were filed for 55 percent of the drugs that made it to Phase III testing, and 80 percent of those gained eventual approval -- though only half were approved on initial review.
The Bedford Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.
Earlier this month BioSante reported positive late stage safety data for its potential blockbuster drug, "LibiGel". LibiGel is designed as a possible treatment for sexual dysfunction in menopausal women. BioSante's senior vice president of medical affairs, Michael C. Snabes, argues that "The need for an FDA-approved treatment to cope with this condition is astonishing."
The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com

Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com (1000 per month).

Tuesday, February 15, 2011

Biotech/Pharma Stock News; BioSante Presents Data Showing Female Sexual Dysfunction is a Significant Unmet Medical Need

LINCOLNSHIRE, Ill. - February 15, 2011 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), a pharmaceutical company developing products for the treatment of female sexual health, presented critical female sexual dysfunction market data at the ISSWSH (The International Society for the Study of Women�s Sexual Health) annual meeting. The data presented include results of a survey of over 100 Obstetrician/Gynecologists and Primary Care Physicians regarding the need for an FDA-approved drug to treat a form of Female Sexual Dysfunction (FSD) known as Hypoactive Sexual Desire Disorder (HSDD).
There are currently no FDA-approved therapeutic treatment options for women with HSDD. A significant number of physicians (over 90 percent) reported that they prescribe off-label testosterone for women to treat FSD, however, these physicians are dissatisfied with the non-FDA approved, off-label alternatives. The physicians indicated that they hear an average of 37 unsolicited inquiries per month from women regarding sexual dysfunction. Nationally, it is estimated that 4.1 million off-label testosterone prescriptions are filled annually.
"The need for an FDA-approved treatment to cope with this condition is astonishing, as stated by the physicians surveyed. This position also was strongly supported by the attendees at the ISSWSH meeting," said Michael C. Snabes, M.D., Ph.D., BioSante�s senior vice president of medical affairs. "It has been more than a decade since the FDA approved Viagra for the treatment of male sexual dysfunction; it is time women have a safe and effective option for the treatment of their sexual health." BioSante is developing LibiGel® (testosterone gel) for the treatment of HSDD in menopausal women. LibiGel is currently in three Phase III clinical studies to prove its safety and efficacy.
The physicians in the survey were asked their reaction to an unnamed therapeutic that fit LibiGel�s profile. An overwhelming 94% responded favorably, as long as it is proven to be safe. To that end, BioSante is conducting a Phase III multicenter cardiovascular and breast cancer safety study. BioSante reported at the ISSWSH meeting that with 2,869 women enrolled and over 3,000 women-years of exposure in its LibiGel Phase III cardiovascular and breast cancer safety study, there have been 17 adjudicated cardiovascular (CV) events, with a lower than anticipated event rate of approximately 0.57 percent. There have been eight breast cancers reported, a rate of approximately 0.27 percent.
The survey, conducted independently for BioSante by Campbell Alliance Group, Inc., revealed sexual dysfunction to be one of the most common complaints received in these doctors� offices. The physicians described themselves as dissatisfied with the current lack of therapeutic options for HSDD, a loss of libido or sexual desire.
About LibiGel®
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD). The on-going Phase III efficacy trials are double-blind, placebo-controlled trials that will enroll up to approximately 500 surgically menopausal women each for a six-month clinical trial. The efficacy trials are being conducted under an FDA-approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time.
In a Phase II trial, LibiGel significantly increased the number of satisfying sexual events in surgically menopausal women suffering from FSD by 238 percent versus baseline (p < 0.0001); this increase also was significant versus placebo (p < 0.05). In this study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. In addition, no serious adverse events and no discontinuations due to adverse events occurred in any subject receiving LibiGel. The Phase II clinical trial was a double-blind, placebo-controlled trial, conducted in the United States, in surgically menopausal women distressed by their low sexual desire and activity.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com

Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com (1000 per month).

Monday, February 14, 2011

Biotech/ Pharma Stock Trading Alert; BioSante Pharmaceuticals Inc up on News

Point Roberts, WA. –February 14, 2011 (Investorideas.com Energy stocks Newswire) -
www.InvestorIdeas.com and its leading Biotech investor portals, announces a technical stock
trading alert for BioSante Pharmaceuticals Inc (NASDAQ:BPAX). The stock is trading at $2.41,
up 0.10 (4.33%), trading as high as $2.53 in morning trading.

Recent News: BioSante Pharmaceuticals (NASDAQ: BPAX) Reports Positive LibiGel Safety
Data in Phase III Program

“LINCOLNSHIRE, Ill. - February 14, 2011 BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX),
presented positive safety data in its ongoing LibiGel Phase III clinical development program, at
the annual meeting of ISSWSH on February 12, 2011.

BioSante reported that with 2,869 women enrolled and over 3,000 women-years of exposure
in its LibiGel Phase III cardiovascular and breast cancer safety study, there have been 17
adjudicated cardiovascular (CV) events, with a lower than anticipated event rate of approximately
0.57 percent. There have been eight breast cancers reported, a rate of approximately 0.27
percent.

Therefore, the Phase III LibiGel (testosterone gel) safety study will continue as per the FDA-
agreed protocol, without modifications including continued enrollment of new subjects. This was
the recommendation of the independent Data Monitoring Committee (DMC) based on its 5th
unblinded review of all study safety data. LibiGel is in development for the treatment of female
sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal
women, for which there is no FDA-approved product.”
Full News at: http://www.investorideas.com/CO/BPAX/news/2011/02142.asp

Recent News: BioSante Pharmaceuticals, Inc. To Present LibiGel®
Safety Study Update At BIO CEO & Investor Conference

“LINCOLNSHIRE, Illinois (February 14, 2011) – BioSante Pharmaceuticals, Inc. (NASDAQ:
BPAX) will be presenting at the 2011 BIO CEO & Investor Conference. Hosted by the
Biotechnology Industry Organization (BIO), the 13th Annual CEO & Investor Conference will take
place February 14-15, 2011 at the Waldorf-Astoria in New York.

Stephen M. Simes, BioSante’s president & CEO, will speak today, Monday February 14, 2011
at 3:30 pm EST. He will provide an overview of the company, as well as an update on LibiGel®
(testosterone gel) Phase III clinical development program including safety data. A live audio
webcast of Mr. Simes’ remarks may be accessed at: http://www.veracast.com/webcasts/bio/

ceoinvestor2011/16113289.cfm .”
Full News at: http://www.investorideas.com/CO/BPAX/news/2011/02141.asp

More info: About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female
sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal
testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III
clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol
Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have
been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other
products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to
Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante
patented technology. The company also is seeking opportunities for its other technologies.
Additional information is available online at: www.biosantepharma.com.

Sign up for the free investor news letter and get stock alerts in leading
sectors! http://www.investorideas.com/Resources/Newsletter.asp

Research more biotech stocks at the Biotech stocks Directory: http://
www.investorideas.com/BIS/Stock_List.asp

About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized
in sector investing, covering leading industry sectors including mining and gold stocks, in addition
to global markets including China, India, the Middle East and Australia. Investorideas.com is
known for its comprehensive stock directories in each sector and sector specific newswires.

About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the
sector, within Investorideas.com. Global visitors use the site daily to research the latest news,
articles, audio, research reports and our stock directories.

Contact BioSante Pharmaceuticals

For Media:
McKinney/Chicago
Alan Zachary
(312) 506-5220; azachary@mckinneychicago.com

For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953; tswanson@troutgroup.com

Investorideas.com Disclosure, Disclaimer/ BPAX is a paid advertising client on
Investorideas.com. (one thousand per month)

Disclaimer: The following news is paid for by BPAX (three thousand per month)
Investorideas.com is a third party publisher of news and research .Our sites do not make
recommendations, but offer information portals to research news, articles, stock lists and
recent research. Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. This site is currently compensated by featured companies, news
submissions and online advertising.

Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp

Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

Source: Investorideas.com, BioSante, Investorideas.com
Contact Investorideas.com to become a biotech showcase stock or research biotech stocks
800 665 0411 cvanzant@investorideas.com

Biotech/Pharma Stock News; BioSante Pharmaceuticals Reports Positive LibiGel Safety Data in Phase III Program

LINCOLNSHIRE, Ill. - February 14, 2011 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), presented positive safety data in its ongoing LibiGel Phase III clinical development program, at the annual meeting of ISSWSH on February 12, 2011.
BioSante reported that with 2,869 women enrolled and over 3,000 women-years of exposure in its LibiGel Phase III cardiovascular and breast cancer safety study, there have been 17 adjudicated cardiovascular (CV) events, with a lower than anticipated event rate of approximately 0.57 percent. There have been eight breast cancers reported, a rate of approximately 0.27 percent.
Therefore, the Phase III LibiGel (testosterone gel) safety study will continue as per the FDA-agreed protocol, without modifications including continued enrollment of new subjects. This was the recommendation of the independent Data Monitoring Committee (DMC) based on its 5th unblinded review of all study safety data. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product.
"Once again, the DMC has recommended that the safety study continue as per the FDA-agreed protocol, without modification as there were no general or specific safety issues based on their unblinded review of adverse events. In addition, the low number of CV events to date is consistent with the safety of testosterone in this population," stated Michael Snabes, M.D., Ph.D., the senior vice president of medical affairs for BioSante. "Once the DMC determines that there are enough subjects enrolled for statistical significance, enrollment of new subjects will be complete. The protocol allows up to 4,000 women to be enrolled, however, the DMC may recommend completion of enrollment at any time between the current enrollment and the 4,000 women maximum."
Subjects have been enrolled in this study for an average of 12.5 months. More than 1,000 subjects have been enrolled in the study for more than a year and over 550 subjects for more than two years. The periodic reviews by the DMC are based on their mandate in accordance with FDA agreement on protocol-defined study oversight. BioSante's objective is to submit the LibiGel NDA for a product launch in 2012.
"LibiGel remains the only product in the world in Phase III clinical development for the treatment of HSDD," said Stephen M. Simes, BioSante's president & CEO. "We expect to announce completion of enrollment in both Phase III efficacy trials in the near-future," Mr. Simes continued. "With this most recent favorable DMC recommendation, we continue to believe that LibiGel will be the first product approved by the FDA to treat HSDD, also referred to as FSD, in menopausal women."
About the LibiGel Phase III Cardiovascular and Breast Cancer Safety Study
The Phase III LibiGel safety study is a randomized, double-blind, placebo-controlled, multi-center, cardiovascular (CV) events and breast cancer study that has enrolled 2,869 women, with a maximum of 4,000 patients to be enrolled. The study will continue for a total of five years, however, BioSante can use the safety study data as part of an NDA submission after an average of 12 months of exposure to LibiGel or placebo.
The LibiGel safety study is tracking a predefined list of CV events, in agreement with the FDA, including CV death, myocardial infarction and stroke in women 50 years of age or older and suffering from at least two CV risk factors including hypertension and diabetes. The objective of the safety study is to show the relative safety of testosterone compared to placebo in the number of CV events. The incidence of breast cancer also is being tracked over the course of the study. The study represents the largest data base of the safety of testosterone in women.
Upon completion of the statistical analyses of the safety study and efficacy trials, BioSante intends to submit an NDA to the FDA, requesting approval to market LibiGel for the treatment of HSDD in menopausal women.
About LibiGel®
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD). The on-going Phase III efficacy trials are double-blind, placebo-controlled trials that will enroll up to approximately 500 surgically menopausal women each for a six-month clinical trial. The efficacy trials are being conducted under an FDA-approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time.
In a Phase II trial, LibiGel significantly increased the number of satisfying sexual events in surgically menopausal women suffering from FSD by 238 percent versus baseline (p<0.0001); this increase also was significant versus placebo (p < 0.05). In this study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. In addition, no serious adverse events and no discontinuations due to adverse events occurred in any subject receiving LibiGel. The Phase II clinical trial was a double-blind, placebo-controlled trial, conducted in the United States, in surgically menopausal women distressed by their low sexual desire and activity.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as �will,� �potential,� �could,� �can,� �believe,� �intends,� �continue,� �plans,� �expects,� �anticipates,� �estimates,� �may,� other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
Visit the BPAX showcase profile at Investorideas.com
Request News and Info on BPAX
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.

Biotech/Pharma Stock News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) To Present LibiGel Safety Study Update at BIO CEO & Investor Conference

LINCOLNSHIRE, Ill. - February 14, 2011 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will be presenting at the 2011 BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 13th Annual CEO & Investor Conference will take place February 14-15, 2011 at the Waldorf-Astoria in New York.
Stephen M. Simes, BioSante�s president & CEO, will speak today, Monday February 14, 2011 at 3:30 pm EST. He will provide an overview of the company, as well as an update on LibiGel� (testosterone gel) Phase III clinical development program including safety data. A live audio webcast of Mr. Simes� remarks may be accessed at: http://www.veracast.com/webcasts/bio/ceoinvestor2011/16113289.cfm
A webcast replay will be available for 90 days beginning one hour after conclusion of the live event.
About The BIO CEO & Investor Conference
Now in its thirteen year, the BIO CEO & Investor Conference 2011 is the largest investor conference focused on the biotechnology industry. The conference provides a forum for public and private equity investors, research analysts, investment bankers and senior-level industry executives to learn about and discuss investment trends and investment opportunities in the biotechnology industry. This year�s conference will feature corporate presentations from more than 120 companies, workshops featuring leading experts on specific therapeutic and technology topics, plenary and panel sessions on timely business issues and industry trends, many opportunities to schedule one-on-one meetings, as well as numerous networking opportunities. For more information, visit www.ceo.bio.org.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
Visit the BPAX showcase profile at Investorideas.com
Request News and Info on BPAX
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.

Thursday, February 10, 2011

BioSante's Senior V.P. Michael Snabes, MD, PhD, to Discuss Data From LibiGel® Safety Study

LINCOLNSHIRE, Ill. - February 10, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) reports it will provide a LibiGel safety study update, in addition to supporting two clinical symposia, at the Annual Meeting of The International Society for the Study of Women's Sexual Health Meeting (ISSWSH).
An estimated 300 experts and practitioners in women's health and female sexual dysfunction (FSD) are expected to attend the meeting, hosted at the Doubletree Paradise Valley resort in Scottsdale, Arizona, February 10-13, 2011.
Michael Snabes, MD, PhD, BioSante's senior vice president of medical affairs, will deliver an oral presentation entitled, "LibiGel� (testosterone gel) Safety Study Continues with a Low Rate of Cardiovascular and Breast Cancer Events," on February 12, 2011 at 3 pm local time. Dr. Snabes will provide an update on the largest-ever safety study comparing low-dose testosterone treatment to placebo treatment, including the LibiGel safety study's low cardiovascular event rate. To date, this ongoing study has enrolled more than 2,800 menopausal women who suffer from Hypoactive Sexual Desire Disorder (HSDD).
The supported symposia are entitled, "Efficacy of Testosterone in Treating Women with HSDD" and "FSD and the FDA: Past, Present & Future." The first symposium, "Efficacy of Testosterone in Treating Women with HSDD," will feature Susan R. Davis, MBBS, FRACP, PhD, Professor of Women's Health and NHMRC Principal Research Fellow and Director, the Women's Health Research Program, Department of Medicine, Monash University, Vic, Australia, and Glenn Braunstein, MD, Department of Medicine, Cedars-Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California.
The second symposium, "FSD and the FDA: Past, Present & Future," will be moderated by Alan Altman, MD, president of ISSWSH. The speakers include Anita H. Clayton, MD, professor of psychiatry and neurobehavioral sciences, and professor of clinical obstetrics and gynecology at the University of Virginia Health Systems; Michael Krychman, MD, medical director of The Sexual Medicine Center in Hoag Hospital in Newport Beach, California; Marianne Brandon, PhD, a clinical psychologist for Wellminds Wellbodies LLC and a diplomat in sex therapy; Julia Heiman, PhD, director of the Kinsey Institute for Research in Sex, Gender, and Reproduction and professor of psychology and clinical psychiatry at Indiana University, as well as Dr. Snabes of BioSante.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel� (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under an FDA Special Protocol Assessment (SPA). BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel�, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
For more information, please contact:
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
Visit the BPAX showcase profile at Investorideas.com
Request News and Info on BPAX
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.

Monday, February 7, 2011

Q&A with Josh Levine of MicroCap Investor; Winning Strategy for Stocks in Biotech, Cleantech, and Emerging Technologies

New York, NY, Point Roberts WA, February 7, 2011 � Investorideas.com, an investor research portal specializing in sector investing including cleantech and biotech, interviews Josh Levine of the MicroCap Investor newsletter to gain insight on his research methodology.
Interview:
Q: Investorideas.com
Josh, your newsletter is unique in that you cover microcap stocks, which most investors associate with day trading -- but you research the space to look for long term wins. Can you tell investors why you look within the microcap space for those opportunities?
A: Josh Levine, MicroCap Investor
I view microcap investing as a long-term process that entails holding stocks one, three, five years and longer. It is endlessly fascinating and rewarding to invest in small companies developing new technologies and innovations, but it does require lots of patience and discipline. Jumping in and out of stocks only creates short term capital gains -- a tax consequence we try to avoid.
Successful microcap investing, above all else, relies on fundamental analysis and not market timing or seasonal variations. As long as investors focus on the market's inefficiencies at this level -- and capitalize on them -- they'll do very well in the long run.
This point about inefficiencies is extremely important. The gaps between the market's perspective and the fundamental realities of a company are vastly wider in smaller stocks than larger ones -- and that's why I‘ve uncovered so many enticing opportunities.
Like the old song goes, "You say potato and I say po-tah-to, you say tomato and I say to-mah-to ..." Similarly, investors in the microsphere seldom agree on the inherent values of these fledgling companies and, more specifically, their potential earnings power several years out.
Of course, that's what makes for a market and that's why there are usually buyers and sellers at almost every price. As they say, one man's trash is another man's treasure. In microcap land, where there are thousands of penny stocks and solid fundamentals are at a premium, there is lots of trash to sift through. Fortunately, I've been around the block enough times to know which neighborhoods hold the real treasures.
Q: Investorideas.com
You have a focus on biotech, cleantech, and other emerging technologies. Can you tell us why those key areas?
A: Josh Levine, MicroCap Investor
Small firms are able to concentrate on high-value-added functions where cutting-edge knowledge and technology are paramount. As a result, the microcaps that execute deliver amazingly high-growth margins and profits -- and fantastic returns to their investors.
By participating in transformational changes in the highest-growth industries, any microcap that successfully navigates the path from R&D to commercialization and beyond will emerge a big winner. There are no better sectors to find these companies than in biotechnology and medical technologies, cleantech and renewable energy, and advanced IT and networking technologies.
The life sciences is a particularly rich group to explore for exciting microcap opportunities. One reason is that big pharma companies are expected to lose as much as $140 billion in annual sales by 2016, as some of their key product patents expire. These drug giants are desperate for new innovations to revitalize their pipelines and small biotechs are an excellent source.
A surprisingly large number of the best microcap prospects reside in the biopharma and biotech sectors. I have always sought out and discovered bio companies with certain valuable attributes. Indeed, compared to the vast majority of sub-$100-million-market-value firms, the biotechs in our portfolio have seasoned management, big-league experienced boards, sane capital structures, enough cash to operate for more than 12 months, and solid partnerships with big pharmas.
In the energy world, for example, the shift to electric transportation will have far-reaching impact on nearly every industry and sector, from energy producers and suppliers to electrical equipment manufacturers and utilities to developers of the smart grid and numerous other advanced IT and energy technologies. Many small companies are building pieces of the emerging infrastructure and smart grids.
It's notable that one of the big boys in global electric infrastructure equipment, ABB, Inc. recently made a $10 million investment in a tiny company that supplies EV charging systems. Mergers and acquisitions will be happening more frequently among companies developing technologies for the smart grid. What's more, the anticipated IPOs this year for cleantech rising stars like Silver Spring Networks and BrightSource Energy will attract new investors.
Electric networks are the largest, most complex systems around, and it will take massive investments in technology over the next couple of decades to get them into shape to meet soaring demand for ever more efficient and ubiquitous electric power. As a consequence, a multitude of opportunities exist for small, innovative firms to capture lucrative market niches.
Q: Investorideas.com
You have just added a new stock to your watch list I understand. Can you tell us the criteria you have in place when you add a new stock and what you typically look for?
A: Josh Levine, MicroCap Investor
First, I want to point out there are variations in my decision-making process between, for instance, a nanocap listed on the OTC Bulletin Board and an established microcap with a $250 million market cap that's profitable with an institutional following.
For the smallest microcaps, it's essential to spend time with management and look at everything with a magnifying glass. For more seasoned companies, there is already a track record as well as more information available, which makes the due diligence process less of a maze.
Obviously, fundamental stock analysis is central, but I've learned that investing in small advanced-tech firms is as much art as science. It comes down to certain basics that apply across the board, and they are:
  • People - starting with the founders and top management, nothing counts more than the quality, experience, track record, and credibility of those running the company.
  • Technology - technologies need to perform well but they also must represent a transformational shift or add significant value by improving current products or systems.
  • Markets - technologies must address a sizable market, or it's simply not worth the effort. Also, it's essential to monitor market trends and being clued in to what industry leaders are doing. As senior analyst for ChangeWave Research, I am able to track the pace of change across many industries.
  • Intangibles - this covers everything under the intellectual property umbrella, from patents to trade secrets, including everything inside the heads of employees. There's nothing tougher to quantify, but it's vital to get as much understanding as you can about these assets.
  • Capital Structure - this reveals a whole lot about a company's history and the ability of executives to manage growth and build for the future. Problems in the capital structure often cripple microcaps, so investors need to be very critical in their analysis.
Q: Investorideas.com
I remember hearing old time investors talking about making their big wins in the market by finding the next big thing and holding on for years. In the past few years that mentality has been dismantled by what transpired in 2008. Do you still see that kind of opportunity in the market - and what kind of wins are you seeing in your portfolio?
A: Josh Levine, MicroCap Investor
Yes, the opportunities for returns of 200%, 500%, 1,000% and higher continue to be out there. But to earn the truly life-altering profits, you need to be fully invested in the best microcap stocks prior to any major bull cycle. A big portion of gains are often made in the early phase of a bull market for microcaps, so you've got to be positioned early. Otherwise, by the time the trend takes shape, it's usually too late to build the kind of low-cost positions that ultimately deliver those ten-bagger profits.
Today I believe we're in the early stages of a microcap bull market, but it's difficult to predict the exact timing. Still, ever since the end of 2008 - even before the general market bottomed - the stocks in the MicroCap Investor portfolio have been trending higher.
We ended 2010 on a high note by capturing a 138% profit by selling one-half of our position in a company that's leading the charge, so to speak, in energy solutions for transportation.
Another microcap in our portfolio, a developer of a new class of cancer therapeutics, is up 240% since I first recommended it to subscribers. When I added this stock to our portfolio it was within pennies of its six-year low. The value of this biotech, which has a long-standing partnership with a leading biopharma and a healthy cash hoard, lies in the ability of its drugs to be used in combination therapies and its excellent prospects for attracting licensees. While its gains so far have been good, this stock could soar five to ten times its current price depending on the success of clinical trials for its various drugs.
In general, our biotech positions are looking very, very good. In less than six months, we're up 43% with a stem cell developer which already has two revenue-generating businesses. And a number of others have been regularly hitting new milestones, which eventually will be translated into much higher market valuations.
While all of the stocks in our portfolio are positioned for tremendous upside ahead, the most consistent performers have been what I call the “Mature Microcaps.” For instance, within this group we've got a gain of 109% with a supplier of advanced equipment for large-scale solar projects, and we're up 76% with a designer of 3G/4G wireless chips.
Finally, one of my favorite microcaps today is a company which has developed and is selling advanced mobile services to multi-billion dollar markets worldwide in dire need of its cost-effective and efficient solutions. We've already got a 120% gain, but I believe this one has all the characteristics of rapidly becoming one of the great microcap winners of the decade.
The recent activity in our micros, nice as it's been, hardly measures up to the bonanzas of past microcap bull runs. A big reason is that this bull market lacks the full participation of the public which has remained enormously risk-adverse after the blow-ups, busts and downturns of the past decade.
Depending on the breadth and length of this upturn, individual investors will increasingly come back into the game, and eventually in large numbers. By then, however, the biggest profits will have been registered by those investors positioned far ahead of the herd.
Josh Levine's MicroCap Investorhttp://www.levinesmicrocapinvestor.com
Levine's MicroCap Investor delves deep into the world of small stocks to identify big winners, targeting innovative companies on the path of the new and revolutionary.
About Josh Levine
Levine has 25 years of senior-level experience in analyzing technology trends and investing in top-performing micro- and small-cap stocks. He excels at assessing management teams and evaluating new innovations and their impact on corporate valuations.
More on Levine's bio: http://www.levinesmicrocapinvestor.com/aboutus/
To learn more about this and the other outstanding investment opportunities in the MicroCap Investor portfolio, subscribe now.
http://www.levinesmicrocapinvestor.com/subscriptions/order/
InvestorIdeas.com is partnered with Josh Levine and MicroCap Investor as part of its mission to provide investors with research tools to explore the world of small stocks. The InvestorIdeas.com team operates this web site and manages the administration and marketing for MicroCap Investor.
InvestorIdeas.com is a leading investment and industry research portal, with resources covering high-growth sectors including technology, biotech and cleantech.
Levine's Microcap Investor
Disclaimer and disclosure for Levine's Microcap :
http://www.levinesmicrocapinvestor.com/disclosure/
Disclaimer and disclosure for Investorideas.com
Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. http://www.investorideas.com/About/Disclaimer.asp
Contact us
admin@levinesmicrocapinvestor.com
800 665 0411

Thursday, February 3, 2011

Biotech/Pharma Profile Update for BioSante Pharmaceuticals, Inc.

Key Highlight: BioSante Pharmaceuticals is Only Company in World In Phase III Clinical Development for Treatment of Female Sexual Dysfunction

Point Roberts, WA, LINCOLNSHIRE, Ill - February 3, 2011 Investorideas.com, a leader in sector research, updates the company profile for BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) for investors following biotech and pharma stocks.
Recent News:
"BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) To Provide Update on LibiGel Safety Study at International Society for the Study of Women's Sexual Health Meeting"
LINCOLNSHIRE, Ill. - February 3, 2011 BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced that it will provide a LibiGel safety study update, and is supporting two clinical symposia at the Annual Meeting of The International Society for the Study of Women's Sexual Health Meeting (ISSWSH) being held from February 10-13, 2011 at the Doubletree Paradise Valley resort in Scottsdale, Arizona. More than 300 experts and practitioners in women's health and female sexual dysfunction (FSD) are expected to attend the meeting.
Read the full news release, click here .
Company Overview:
BioSante (NASDAQ: BPAX) is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. www.biosantepharma.com
The BPAX company profile is available at http://www.investorideas.com/CO/BPAX/ for interested biotech investors.
Read the full BPAX Investor Presentation at: http://www.investorideas.com/CO/BPAX/news/2011/BPAX-Presentation-012111.pdf
Financial Highlights
  • At December 31, 2010, BioSante had approximately $39M in cash
  • Monthly burn rate of approximately $3.5M - $4.0M
Trading Data
  • NASDAQ: BPAX
  • Recent Price (2/2/11): $1.93
  • Market Cap: $150M
  • Average Daily Volume: 1.1M
  • Common Shares Outstanding: 81.4M
  • 52-Week Range: $1.29-$2.50
  • Fiscal Year Ends: December 31
Investment Highlights
  • Financial resources to continue corporate strategy
  • Late stage pharmaceutical product portfolio with significant growth potential
  • LibiGel in three ongoing Phase III safety and efficacy clinical studies
  • Elestrin is FDA approved and marketed in the U.S.
  • Proprietary cancer vaccines in Phase II clinical trials
  • Focused growth strategy
  • Management's proven ability to gain FDA approval, implement plans and increase stockholder value
LibiGel Facts
Full LibiGel Brochure at: http://www.investorideas.com/CO/BPAX/news/2011/LibiGel-Brochure-Jan2011.pdf
LibiGel®* Treatment of Women with
Hypoactive Sexual Desire Disorder (HSDD)
LibiGel® is a gel formulation of testosterone in development that is quickly absorbed through the skin after a once-daily application of a pea-sized dose of gel on the upper arm, delivering testosterone to the bloodstream evenly over time and in a non-invasive and painless manner. Though generally characterized as a male hormone, testosterone also is present in women and its deficiency has been found to decrease libido or sex drive. In addition, studies have shown that testosterone therapy can increase bone density, raise energy levels and improve mood, in addition to boosting sexual desire and activity.
Regulatory Status
The LibiGel clinical development program, in consultation and agreement with the FDA, has been designed to show that LibiGel can safely improve women's sexual desire and the frequency of satisfying sexual events and decrease personal distress associated with low sexual desire in women with HSDD. BioSante is conducting three Phase III LibiGel clinical studies and BioSante's objective is to submit a new drug application (NDA) to the FDA in 2011 for a potential approval in 2012.
Progress and Plans in Phase III:
Currently, BioSante is conducting three Phase III clinical studies to demonstrate the safety and efficacy of LibiGel to increase sexual desire and satisfying sexual events and to decrease distress associated with the decreased desire. Two Phase III safety and efficacy trials that are underway are randomized, double blind, placebo-controlled trials which will enroll approximately 500 surgically menopausal women each for six-months of treatment. BioSante is conducting these trials under an FDA agreed special protocol assessment (SPA). In addition, BioSante has another SPA agreement with the FDA related to treatment of naturally menopausal women. The SPA process and agreement confirms the FDA's position that FSD and HSDD are true conditions that women experience, with measurable endpoints, that can be evaluated and which deserve therapeutic options. It also affirms that the FDA agrees that the LibiGel Phase III safety and efficacy clinical trial design, clinical endpoints, sample size, planned conduct and statistical analyses are acceptable to support regulatory approval. Further, it provides assurance that these agreed measures will serve as the basis for regulatory review and the decision by the FDA to approve an NDA for LibiGel.
In addition to the two Phase III safety and efficacy trials covered by the SPA, BioSante is conducting one Phase III cardiovascular and breast cancer safety study of LibiGel, which also is underway. The safety study is a randomized, double-blind, placebo-controlled, multi-center, cardiovascular events and breast cancer study of between 2,750 and
4,000 women exposed to LibiGel or placebo. BioSante will follow the women enrolled in the safety study for a total of 5 years. However, after an average of 12 months' exposure BioSante intends to submit a LibiGel NDA for review and potential approval by FDA.
The LibiGel safety study is tracking a composite of cardiovascular events including cardiovascular death, myocardial infarction and stroke in women with FSD who are 50 years of age or older and have at least two cardiovascular risk factors such as hypertension and diabetes. The objective of the safety study is to show the relative safety of testosterone compared to placebo in the number of cardiovascular events. The incidence of breast cancer also will be tracked throughout the study.
BioSante has reported that in the first 2,750 women enrolled comprising approximately 2,700 women-years of exposure, there have been only 14 adjudicated cardiovascular events even though the safety study is enrolling women with a higher risk of cardiovascular events. To date, over 2,750 women have been enrolled.
BioSante's obective is to submit the LibiGel NDA in 2011 for a potential FDA approval in 2012.
Contact BioSante Pharmaceuticals
For Media:
McKinney/Chicago
Alan Zachary
(312) 506-5220; azachary@mckinneychicago.com
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953; tswanson@troutgroup.com
To the extent any statements made in this news release deal with information that is not hist orical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Disclaimer: This news release is part of a monthly information distribution program for BioSante (BPAX) (one thousand dollars per month). Investorideas.com is a third party publisher of news and research .All information on featured companies is prepared by the company or taken from public filings and news releases. Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
About InvestorIdeas.com :
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech/pharma, mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
Visit our Biotech investor portal : www.biotechindustrystocks.com
Research more biotech stocks at the Biotech stocks Directory
Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp  
Source: Investorideas.com, BioSante Pharmaceuticals Inc.
Contact Investorideas.com to become a biotech showcase stock or research biotech stocks
800 665 0411: cvanzant@investorideas.com
Visit the BPAX showcase profile at Investorideas.com
Request News and Info on BPAX
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.